A new item for dihydropyrimidine dehydrogenase (DPYD) genotyping to diagnose or predict fluoropyrimidine (FP)-induced toxicity will be listed on the Australian Medicare Benefits Schedule (MBS), effective 1 November 2025.
This new pathology service item, MBS item 73322, will allow patients with solid tumours who are receiving, about to commence, or have previously received FP-based chemotherapy (such as 5-fluorouracil or capecitabine) to access a Medicare rebate for the test.